Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Recommendation of "Buy" by Analysts

Summary by marketbeat.com
Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been given a consensus recommendation of "Buy" by the seventeen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, thirteen have given

1 Articles

marketbeat.commarketbeat.com
Center

Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Recommendation of "Buy" by Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been given a consensus recommendation of "Buy" by the seventeen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, thirteen have given

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

marketbeat.com broke the news in on Monday, August 25, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Denali icon

Denali

News
For You
SearchBlindspotLocal